Jefferies Global Healthcare Conference
Logotype for Viking Therapeutics Inc

Viking Therapeutics (VKTX) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Viking Therapeutics Inc

Jefferies Global Healthcare Conference summary

18 Nov, 2026

VK2735 maintenance results

  • At Week 21, weekly VK2735 produced 16.3%–18.7% weight loss across dose groups; the 17.5 mg cohort lost 17.8% (n=118), with no plateau observed.

  • After switching from weekly dosing, participants maintained up to 96.7% of Week 21 weight loss with every-other-week dosing and up to 90.2% with monthly dosing through Week 33; placebo participants regained ~40% of initial weight loss by Week 12.

  • Continued 17.5 mg weekly dosing produced 21.7% weight loss from baseline at Week 33, with no plateau observed.

  • Maintenance-phase GI adverse-event rates were similar to placebo, with low GI event rates after titration; early discontinuation was 3% with every-other-week and 5% with monthly dosing.

  • ApoB, non-HDL cholesterol and triglyceride effects tracked weight loss and remained consistent through maintenance.

Maintenance studies and dosing options

  • Part 2 evaluates transition from 17.5 mg weekly subQ to daily oral doses of 10–55 mg; a second study adds six higher-dose subQ arms for every-other-week and monthly dosing, with results expected in 2027 and around mid-year, respectively.

  • Monthly dosing retention was 90%; 35 mg monthly is being explored in a VANQUISH extension, with data intended for conference presentations and potential label language.

  • Potential maintenance options include weekly, every-other-week and monthly dosing, or transition from injection to oral therapy; oral maintenance targets retaining at least 75% of initial weight loss, particularly at mid-to-high doses.

  • A study switching patients from existing injectable treatments to VK2735 is considered worthwhile but is not planned near term.

  • Longer follow-up is planned in VANQUISH extensions through 52 weeks.

Phase 3 programs and market opportunity

  • VANQUISH-1 and VANQUISH-2 evaluate weekly subcutaneous VK2735 for 78 weeks; enrollment completed in 4Q25 and 1Q26, respectively, with data expected in 2H27.

  • SUNRISE-1 and SUNRISE-2 evaluate daily oral VK2735 for 68 weeks in obesity and obesity with diabetes; both began in 4Q26, target 560 participants each, and are expected to report data in 2028.

  • Four Phase 3 trials are underway; first Phase 3 data are targeted for H2 2027.

  • The obesity market is projected to exceed $150B by 2035, with a stated 16% CAGR; VK2735 is positioned for oral and injectable use and potential entry as the third obesity franchise.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Viking Therapeutics